Silverberg Bernstein Capital Management LLC Sells 144 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Silverberg Bernstein Capital Management LLC reduced its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 0.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,129 shares of the medical equipment provider’s stock after selling 144 shares during the period. Lantheus makes up 1.6% of Silverberg Bernstein Capital Management LLC’s investment portfolio, making the stock its 16th largest holding. Silverberg Bernstein Capital Management LLC’s holdings in Lantheus were worth $1,801,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Victory Capital Management Inc. lifted its position in Lantheus by 18.5% in the 2nd quarter. Victory Capital Management Inc. now owns 25,705 shares of the medical equipment provider’s stock valued at $2,064,000 after acquiring an additional 4,021 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of Lantheus by 0.3% in the second quarter. Envestnet Asset Management Inc. now owns 111,498 shares of the medical equipment provider’s stock valued at $8,952,000 after purchasing an additional 356 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Lantheus by 1.6% during the second quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider’s stock valued at $99,525,000 after buying an additional 19,071 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Lantheus by 142.8% during the second quarter. Renaissance Technologies LLC now owns 215,431 shares of the medical equipment provider’s stock worth $17,297,000 after buying an additional 126,700 shares in the last quarter. Finally, Peregrine Asset Advisers Inc. bought a new position in Lantheus during the 2nd quarter valued at $3,669,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Trading Up 1.5 %

Shares of Lantheus stock opened at $94.05 on Wednesday. The company’s 50-day moving average price is $89.53 and its 200-day moving average price is $99.87. The company has a market cap of $6.54 billion, a price-to-earnings ratio of 15.65 and a beta of 0.46. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Truist Financial reissued a “buy” rating and set a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday. Finally, The Goldman Sachs Group began coverage on Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $131.86.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.